Debye temperature of disordered bcc-Fe-Cr alloys

Debye temperature, TD, of Fe100-xCrx disordered alloys with 0<x<99.9 was determined from the temperature dependence of the centre shift of 57Fe Mossbauer spectra recorded in the temperature range of 80-300K. Its compositional dependence shows an interesting non-monotonous behaviour. For 0<x<~45 as well as for ~75<x<~95 the Debye temperature is enhanced relative to its value of a metallic iron, and at x=~3 there is a local maximum having a relative height of ~12% compared to a pure iron. For ~45~95 the Debye temperature is smaller than the one for the metallic iron, with a local minimum at x=~55 at which the relative decrease of TD amounts to ~12%. The first maximum coincides quite well with that found for the spin-waves stiffness coefficient, D0, while the pretty steep decrease observed for x>~95 which is indicative of a decoupling of the probe Fe atoms from the underlying chromium matrix is likely related to the spin-density waves which constitute the magnetic structure of chromium in that interval of composition. The harmonic force constant calculated from the Debye temperature of the least Fe-concentrated alloy (x>99.9) amounts to only 23% of the one characteristic of a pure chromium.Comment: 15 pages, 7 figures, 26 reference

Sigma-phase in Fe-Cr and Fe-V alloy systems and its physical properties

A review is presented on physical properties of the sigma-phase in Fe-Cr and Fe-V alloy systems as revealed both with experimental -- mostly with the Mossbauer spectroscopy -- and theoretical methods. In particular, the following questions relevant to the issue have been addressed: identification of sigma and determination of its structural properties, kinetics of alpha-to-sigma and sigma-to-alpha phase transformations, Debye temperature and Fe-partial phonon density of states, Curie temperature and magnetization, hyperfine fields, isomer shifts and electric field gradients.Comment: 26 pages, 23 figures and 83 reference

Long-time behavior of an angiogenesis model with flux at the tumor boundary

This paper deals with a nonlinear system of partial differential equations modeling a simplified tumor-induced angiogenesis taking into account only the interplay between tumor angiogenic factors and endothelial cells. Considered model assumes a nonlinear flux at the tumor boundary and a nonlinear chemotactic response. It is proved that the choice of some key parameters influences the long-time behaviour of the system. More precisely, we show the convergence of solutions to different semi-trivial stationary states for different range of parameters.Comment: 17 page

Evidence for Different Freeze-Out Radii of High- and Low-Energy Pions Emitted in Au+Au Collisions at 1 GeV/nucleon

Double differential production cross sections of negative and positive pions and the number of participating protons have been measured in central Au+Au collisions at 1 GeV per nucleon incident energy. At low pion energies the pi^- yield is strongly enhanced over the pi^+ yield. The energy dependence of the pi^-/pi^+ ratio is assigned to the Coulomb interaction of the charged pions with the protons in the reaction zone. The deduced Coulomb potential increases with increasing pion c.m. energy. This behavior indicates different freeze-out radii for different pion energies in the c.m.~frame.Comment: IKDA is the Institute for Nuclear Physics in Darmstadt/German

Safe lipid nanocapsule-based gel technology to target lymph nodes and combat mediastinal metastases from an orthotopic non-small-cell lung cancer model in SCID-CB17 mice

The purpose of this study is the assessment of gel technology based on a lauroyl derivative of gemcitabine encapsulated in lipid nanocapsules delivered subcutaneously or intravenously after dilution to target lymph nodes, induce less systemic toxicity and combat mediastinal metastases from an orthotopic model of human, squamous, non-small-cell lung cancer Ma44-3 cells implanted in severe combined immunodeficiency mice. The gel technology mainly targeted lymph nodes as revealed by the biodistribution study. Moreover, the gel technology induced no significant myelosuppression (platelet count) in comparison with the control saline group, unlike the conventional intravenous gemcitabine hydrochloride treated group (P &lt; 0.05). Besides, the gel technology, delivered subcutaneously twice a week, was able to combat locally mediastinal metastases from the orthotopic lung tumor and to significantly delay death (P &lt; 0.05) as was the diluted gel technology delivered intravenously three times a week

Adenosine A2A receptors in Parkinson’s disease treatment

Latest results on the action of adenosine A2A receptor antagonists indicate their potential therapeutic usefulness in the treatment of Parkinson’s disease. Basal ganglia possess high levels of adenosine A2A receptors, mainly on the external surfaces of neurons located at the indirect tracts between the striatum, globus pallidus, and substantia nigra. Experiments with animal models of Parkinson’s disease indicate that adenosine A2A receptors are strongly involved in the regulation of the central nervous system. Co-localization of adenosine A2A and dopaminergic D2 receptors in striatum creates a milieu for antagonistic interaction between adenosine and dopamine. The experimental data prove that the best improvement of mobility in patients with Parkinson’s disease could be achieved with simultaneous activation of dopaminergic D2 receptors and inhibition of adenosine A2A receptors. In animal models of Parkinson’s disease, the use of selective antagonists of adenosine A2A receptors, such as istradefylline, led to the reversibility of movement dysfunction. These compounds might improve mobility during both monotherapy and co-administration with L-DOPA and dopamine receptor agonists. The use of adenosine A2A receptor antagonists in combination therapy enables the reduction of the L-DOPA doses, as well as a reduction of side effects. In combination therapy, the adenosine A2A receptor antagonists might be used in both moderate and advanced stages of Parkinson’s disease. The long-lasting administration of adenosine A2A receptor antagonists does not decrease the patient response and does not cause side effects typical of L-DOPA therapy. It was demonstrated in various animal models that inhibition of adenosine A2A receptors not only decreases the movement disturbance, but also reveals a neuroprotective activity, which might impede or stop the progression of the disease. Recently, clinical trials were completed on the use of istradefylline (KW-6002), an inhibitor of adenosine A2A receptors, as an anti-Parkinson drug